About 75% of menopausal women experience hot flashes, lasting a median 7.4 years. First-line treatment is transdermal estradiol + micronized progesterone (75-90% reduction in RCTs). Non-hormonal options include fezolinetant (Veozah, FDA-approved 2023), paroxetine (Brisdelle), gabapentin, and venlafaxine. Telehealth providers (Midi, Alloy, Evernow) prescribe all options.
Why this happens
Hot flashes (vasomotor symptoms) result from estrogen withdrawal disrupting hypothalamic thermoregulation. The KNDy neuron system in the hypothalamus, normally suppressed by estrogen, becomes hyperactive — triggering inappropriate heat-dissipation responses (vasodilation, sweating).
Trigger frequency varies from 1 per day to multiple per hour. Nocturnal hot flashes disrupt sleep, compounding daytime symptoms via fatigue, mood, and cognitive effects. SWAN cohort data show median vasomotor symptom duration of 7.4 years; African American women experience longest median duration (~10 years).
Common triggers: alcohol, caffeine, spicy food, hot environments, stress, and tight clothing. Individual trigger patterns vary widely.
Most effective intervention — reduces hot flashes 75-90% in RCTs. NAMS 2022 favors transdermal estradiol + micronized progesterone for women < 60 within 10 years of menopause without contraindications.
Pros
Highest efficacy of all options
Addresses multiple symptoms simultaneously
Bone and cardiovascular benefits with early initiation
FDA-approved + insurance-coverable
Cons
Contraindicated in estrogen-positive breast cancer history, active VTE
Slight VTE risk (transdermal lowers vs oral)
Requires monitoring
Fezolinetant (Veozah)
FDA-approved 2023 for moderate-to-severe vasomotor symptoms. Neurokinin 3 receptor antagonist — directly targets the hypothalamic mechanism. Non-hormonal. Effective when HRT is contraindicated.
Pros
Non-hormonal — safe in breast cancer history
Reduces hot flashes ~50-65% in trials
Improves sleep
No weight, sexual function side effects
Cons
Liver enzyme monitoring required (boxed warning since 2024)
FDA-approved low-dose paroxetine specifically for vasomotor symptoms. Minimal antidepressant effect at this dose. ~33-65% hot flash reduction.
Pros
FDA-approved indication
Improves mood comorbidities
Generic available
Cons
Interacts with tamoxifen (avoid in breast cancer history)
GI side effects, sexual dysfunction
Discontinuation syndrome risk
Gabapentin (off-label)
Anticonvulsant with direct vasomotor benefit. Most effective when taken before bedtime — addresses nocturnal hot flashes + sleep simultaneously. Generic, inexpensive.
Pros
Non-hormonal
Direct sleep induction
Reduces hot flashes ~45-50%
Generic $10-$25/month
Cons
Daytime sedation initial 2-4 weeks
Cognitive side effects (concentration)
Off-label use
Venlafaxine (off-label)
SNRI with established efficacy for hot flashes. Useful when HRT contraindicated and mood symptoms also present. Doses 37.5-75 mg/day.
Pros
Treats vasomotor symptoms + mood
Safe in breast cancer history
Generic inexpensive
Cons
Off-label use
Discontinuation syndrome (taper slowly)
Sexual dysfunction, BP increase
When to see a clinician
Hot flashes occur ≥10x/day or severely disrupt sleep
Vasomotor symptoms impair work, mood, or quality of life
Comorbidities (estrogen-sensitive cancer history, VTE) complicate HRT decision
Comprehensive hormone optimization for perimenopausal and menopausal women — bioidentical HRT with lab-driven dosing.
FAQ(5)
How long do menopausal hot flashes last?
SWAN cohort data show median duration of 7.4 years. ~10% of women experience hot flashes for 12+ years. Untreated vasomotor symptoms typically peak in late perimenopause and first 2-3 years postmenopause, then gradually decline. With treatment, symptoms typically improve within 4-12 weeks of starting HRT or fezolinetant.
Is fezolinetant (Veozah) safer than HRT?
Different risk profiles. Fezolinetant is non-hormonal — safer in estrogen-sensitive cancer history. However it carries a 2024 FDA boxed warning for liver toxicity requiring monitoring. HRT has known cardiovascular and breast cancer risk patterns (well-characterized over decades). Choice depends on individual contraindications.
Can I use black cohosh, soy, or OTC supplements?
Evidence is mixed. Some studies show modest benefit (10-20% hot flash reduction); others show no effect vs placebo. Safety is generally favorable but not zero (black cohosh has rare liver toxicity reports). Quality varies dramatically between brands. Reasonable trial for 3 months if symptoms are mild; not a substitute for pharmacotherapy in severe cases.
Will hot flashes return when I stop HRT?
Often yes — especially if HRT is stopped within a few years of menopause when underlying vasomotor symptoms are most active. Tapering rather than abrupt discontinuation reduces rebound severity. Many women restart HRT after experiencing return of symptoms; intermittent HRT use is acceptable per current guidelines.
What's the fastest non-hormonal hot flash relief?
Gabapentin taken 1-2 hours before bed produces sleep benefit on night 1 and vasomotor improvement within 1-2 weeks. Fezolinetant and SSRIs/SNRIs take 4-8 weeks to reach full effect. Behavioral interventions (cool environment, breathable clothing, paced breathing) help acutely but don't address underlying frequency.